RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Relay Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$17.09+0.81 (+4.98%)

Close on Oct 19, 2026

Market cap: $3.47B
P/E (TTM): –
Dividend yield: –

Relay Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	15	10	26	1.38	3.03	83	–
Research & Development	261	319	330	246	173	100	70
General & Administrative	57	77	75	66	57	39	14
Operating Expenses	318	382	399	301	368	138	84
Operating Income	-303	-372	-373	-299	-365	-56	-84
Interest & Investment Income	27	35	31	8.79	0.83	3.40	8.80
Other Non-Operating Income	26	35	31	8.77	0.83	3.38	8.74
Asset Impairment Charges	–	0	0	0	0	0	0
Gain (Loss) on Investments	–	0.10	–	–	–	–	–
Gain (Loss) on Sale of Assets	-1.00	–	–	–	–	–	0.06
Income Tax Expense	0	0	0	0	0	0	0
Income from Continuing Operations	–	–	–	–	-364	-230	-75
Net Income	-276	-338	-342	-291	-364	-52	-75
Preferred Dividends	–	–	–	–	–	0	0
Net Income to Common	–	–	–	–	-364	-230	-75
EPS (Basic)(per share)	-1.61	-2.36	-2.79	-2.59	-3.82	-5.40	-21.82
EPS (Diluted)(per share)	-1.61	-2.36	-2.79	-2.59	-3.82	-5.40	-21.82
Shares Outstanding (Basic, Weighted)(shares)	172	143	123	112	95	43	3.45
Shares Outstanding (Diluted, Weighted)(shares)	172	143	123	112	95	43	3.45

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2999.4%
Net margin: -2763.6%
Return on equity, FY2025: -41.1%

Financial strength

Current ratio: 18.27
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 238.5%

Valuation

P/E ratio: –
Price to sales: 334.95
Price to book: 3.90
Dividend yield: –